Menopause affects approximately 75% of women by age 51, with an estimated 40-60% experiencing moderate to severe symptoms. Despite this prevalence, only about 6% of women use menopausal hormone therapy (MHT). The endocrine and reproductive systems are primarily involved, leading to symptoms that are often underrecognized or misattributed. This underrecognition poses significant challenges for effective management and quality of life. For more on symptom prevalence, visit the NIH resource.
Health
Conclusion Understanding the broad range of benefits associated with menopausal hormone therapy (MHT) is essential for informed, proactive health management during the menopausal transition. Timely evaluation…